KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Assets Average: 2009-2025

Historic Assets Average for Halozyme Therapeutics (HALO) over the last 17 years, with Sep 2025 value amounting to $2.1 billion.

  • Halozyme Therapeutics' Assets Average rose 4.59% to $2.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 billion, marking a year-over-year increase of 4.59%. This contributed to the annual value of $1.9 billion for FY2024, which is 6.21% up from last year.
  • Latest data reveals that Halozyme Therapeutics reported Assets Average of $2.1 billion as of Q3 2025, which was up 0.58% from $2.1 billion recorded in Q2 2025.
  • In the past 5 years, Halozyme Therapeutics' Assets Average ranged from a high of $2.1 billion in Q3 2025 and a low of $773.3 million during Q1 2021.
  • In the last 3 years, Halozyme Therapeutics' Assets Average had a median value of $1.9 billion in 2024 and averaged $1.9 billion.
  • Per our database at Business Quant, Halozyme Therapeutics' Assets Average soared by 110.39% in 2021 and then fell by 2.16% in 2023.
  • Halozyme Therapeutics' Assets Average (Quarterly) stood at $1.1 billion in 2021, then soared by 61.85% to $1.9 billion in 2022, then declined by 2.16% to $1.8 billion in 2023, then grew by 15.32% to $2.1 billion in 2024, then climbed by 4.59% to $2.1 billion in 2025.
  • Its Assets Average stands at $2.1 billion for Q3 2025, versus $2.1 billion for Q2 2025 and $2.1 billion for Q1 2025.